Literature DB >> 30130521

Activity of paraoxonase 1 (PON1) on HDL2 and HDL3 subclasses in renal disease.

Milica Miljkovic1, Aleksandra Stefanovic2, Jelena Vekic2, Aleksandra Zeljkovic2, Tamara Gojkovic2, Sanja Simic-Ogrizovic3, Natasa Bogavac-Stanojevic2, Darko Cerne4, Jasmina Ilic5, Ivan Stefanovic5, Zorana Jelic-Ivanovic2, Vesna Spasojevic-Kalimanovska2, Jelena Kotur-Stevuljevic2.   

Abstract

INTRODUCTION: Cardiovascular complications, as the main cause of mortality in renal patients, are followed with altered lipoproteins composition. Considering that paraoxonase-1 (PON1) is an anti-oxidative enzyme located mainly on HDL particles, the current study has aim to investigate whether failure of kidney function leads to changes in the distribution of PON1 activity between different HDL subclasses.
MATERIALS AND METHODS: In 77 renal patients (21 chronic kidney disease (CKD) and 56 end stage renal disease (ESRD) patients on dialysis) and 20 healthy subjects PON1 activity on HDL2 and HDL3 subclasses was determined by zymogram method that combines gradient gel electrophoresis separation of HDL subclasses and measurement of PON1 activity in the same gel.
RESULTS: Serum paraoxonase (p<0.01) and arylesterase activity (p<0.001) of PON1 as well as its concentration (p<0.01) were significantly lower in CKD and ESRD patients compared to controls. Relative proportion of HDL3 subclasses was higher in ESRD patients than in healthy participants, while HDL2 subclasses was significantly decreased in CKD (p<0.05) and ESRD (p<0.001) patients, as compared to controls. Furthermore, control subjects had higher PON1 activity on HDL2 (CKD and ESRD patients p<0.001) and HDL3 (CKD p<0.05; ESRD patients p<0.001) subclasses in comparison with the both patients groups. Also, significant negative correlation was found between paraoxonase activity of PON1 in serum and creatinine concentration (ρ=-0.373, p<0.01).
CONCLUSIONS: This study showed that altered HDL subclasses distribution, changed PON1 activities on different HDL subclasses as well as diminished anti-oxidative protection could be important factors in atherosclerosis development in CKD and ESRD patients.
Copyright © 2018 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dyslipidaemia; HDL subclasses; Paraoxonase-1

Mesh:

Substances:

Year:  2018        PMID: 30130521     DOI: 10.1016/j.clinbiochem.2018.08.006

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  9 in total

1.  Oxidised high-density lipoprotein in sarcopenia: a pilot study.

Authors:  Kazuhiko Kotani; Akihiro Saitsu
Journal:  Arch Med Sci Atheroscler Dis       Date:  2022-07-07

2.  Arylesterase activity of paraoxonase 1 (PON1) on HDL3 and HDL2: Relationship with Q192R, C-108T, and L55M polymorphisms.

Authors:  Sandra Y Valencia C; Carlos A Isaza M; Julieta Henao B; Leonardo Beltrán A; Nelsy Loango; Patricia Landázuri
Journal:  Biochem Biophys Rep       Date:  2021-03-18

3.  Paraoxonase-1 Regulation of Renal Inflammation and Fibrosis in Chronic Kidney Disease.

Authors:  Fatimah K Khalaf; Chrysan J Mohammed; Prabhatchandra Dube; Jacob A Connolly; Apurva Lad; Usman M Ashraf; Joshua D Breidenbach; Robin C Su; Andrew L Kleinhenz; Deepak Malhotra; Amira F Gohara; Steven T Haller; David J Kennedy
Journal:  Antioxidants (Basel)       Date:  2022-04-30

4.  Plasma Levels of Preβ1-HDL Are Significantly Elevated in Non-Dialyzed Patients with Advanced Stages of Chronic Kidney Disease.

Authors:  Agnieszka Kuchta; Agnieszka Ćwiklińska; Monika Czaplińska; Ewa Wieczorek; Barbara Kortas-Stempak; Anna Gliwińska; Kamil Dąbkowski; Kornelia Sałaga-Zaleska; Agnieszka Mickiewicz; Alicja Dębska-Ślizień; Ewa Król; Maciej Jankowski
Journal:  Int J Mol Sci       Date:  2019-03-09       Impact factor: 5.923

5.  Paraoxonase 1 concerning dyslipidaemia, cardiovascular diseases, and mortality in haemodialysis patients.

Authors:  Alicja E Grzegorzewska; Paulina Adamska; Ewa Iwańczyk-Skalska; Kamila Ostromecka; Leszek Niepolski; Wojciech Marcinkowski; Adrianna Mostowska; Wojciech Warchoł; Czesław Żaba; Paweł P Jagodziński
Journal:  Sci Rep       Date:  2021-03-24       Impact factor: 4.379

6.  Glucose Metabolism Disorders: Challenges and Opportunities for Diagnosis and Treatment.

Authors:  Jelena Vekic; José Silva-Nunes; Manfredi Rizzo
Journal:  Metabolites       Date:  2022-07-29

Review 7.  Subpopulations of High-Density Lipoprotein: Friends or Foes in Cardiovascular Disease Risk in Chronic Kidney Disease?

Authors:  Susana Coimbra; Flávio Reis; Maria João Valente; Susana Rocha; Cristina Catarino; Petronila Rocha-Pereira; Maria Sameiro-Faria; Elsa Bronze-da-Rocha; Luís Belo; Alice Santos-Silva
Journal:  Biomedicines       Date:  2021-05-16

Review 8.  Current Understanding of the Relationship of HDL Composition, Structure and Function to Their Cardioprotective Properties in Chronic Kidney Disease.

Authors:  Gunther Marsche; Gunnar H Heine; Julia T Stadler; Michael Holzer
Journal:  Biomolecules       Date:  2020-09-21

Review 9.  Revealing the Role of High-Density Lipoprotein in Colorectal Cancer.

Authors:  Aleksandra Zeljkovic; Jelena Vekic; Marija Mihajlovic; Tamara Gojkovic; Sandra Vladimirov; Dejan Zeljkovic; Vesna Spasojevic-Kalimanovska; Bratislav Trifunovic
Journal:  Int J Mol Sci       Date:  2021-03-25       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.